Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AnaptysBio, Inc. - Common Stock (NQ:ANAB)

58.81 -6.18 (-9.51%)
Streaming Delayed Price Updated: 12:49 PM EDT, Mar 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 473,580
Open 65.16
Bid (Size) 58.54 (100)
Ask (Size) 59.82 (200)
Prev. Close 64.99
Today's Range 55.61 - 66.28
52wk Range 15.40 - 68.39
Shares Outstanding 27,433,359
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement
From AnaptysBio, Inc.
Via GlobeNewswire

Performance

YTD
+30.8%
+30.8%
1 Month
+6.1%
+6.1%
3 Month
+17.4%
+17.4%
6 Month
+166.8%
+166.8%
1 Year
+223.3%
+223.3%

More News

Read More
News headline image
Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Participation at Upcoming Investor Conferences
From AnaptysBio, Inc.
Via GlobeNewswire
ANAPTYBIO INC (NASDAQ:ANAB) Offers High-Growth Momentum and a Bullish Technical Setup ↗
Via Chartmill
ANAPTYSBIO INC (NASDAQ:ANAB) Shows Minervini Trend Template and High-Growth Momentum Alignment ↗
Via Chartmill
ANAB Stock Falls After It Sues GSK Unit Tesaro Again, Claims Fresh Breach Of 2014 Deal ↗
Via Stocktwits
Topics Lawsuit
News headline image
What This Insider Trim at AnaptysBio Means for Investors After a 260% Stock Rally ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What Investors Should Know About a $163K AnaptysBio Insider Sale ↗
Via The Motley Fool
Topics Intellectual Property Regulatory Compliance
News headline image
Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
AnaptysBio Inc (NASDAQ:ANAB) Meets Minervini Trend Template with High-Growth Momentum ↗
Via Chartmill
News headline image
Anaptys Announces Participation in December Investor Conferences
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
AnaptysBio Inc (NASDAQ:ANAB) Screens as a High-Growth Momentum Leader ↗
Via Chartmill
News headline image
Anaptys Announces $100 Million Stock Repurchase Plan
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
ANAPTYSBIO INC (NASDAQ:ANAB) Shows High-Growth Momentum and Positive Technical Setup ↗
Via Chartmill
News headline image
AnaptysBio To Save $10 Million After Discontinuing Ulcerative Colitis Study ↗
Via Benzinga
News headline image
Why AnaptysBio Stock Plummeted, Reversing A 70% Monthlong Run ↗
Via Investor's Business Daily
News headline image
Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Participation in November Investor Conferences
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Wall Street Climbs Despite Shutdown Risk — Pfizer and CoreWeave Shine Bright ↗
Via Chartmill
Topics Artificial Intelligence

Frequently Asked Questions

Is AnaptysBio, Inc. - Common Stock publicly traded?
Yes, AnaptysBio, Inc. - Common Stock is publicly traded.
What exchange does AnaptysBio, Inc. - Common Stock trade on?
AnaptysBio, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for AnaptysBio, Inc. - Common Stock?
The ticker symbol for AnaptysBio, Inc. - Common Stock is ANAB on the Nasdaq Stock Market
What is the current price of AnaptysBio, Inc. - Common Stock?
The current price of AnaptysBio, Inc. - Common Stock is 58.81
When was AnaptysBio, Inc. - Common Stock last traded?
The last trade of AnaptysBio, Inc. - Common Stock was at 03/27/26 12:49 PM ET
What is the market capitalization of AnaptysBio, Inc. - Common Stock?
The market capitalization of AnaptysBio, Inc. - Common Stock is 1.61B
How many shares of AnaptysBio, Inc. - Common Stock are outstanding?
AnaptysBio, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.